Multipoint targeting of the PI3K/mTOR pathway in mesothelioma

British Journal of Cancer

Volumn 110, Issue 10, 2014, Pages 2479-2488

  Zhou, S ^a,b   Liu, L ^a   Li, H ^a   Eilers, G ^c   Kuang, Y ^d   Shi, S ^a   Yan, Z ^a   Li, X ^a   Corson, J M ^c   Meng, F ^a   Zhou, H ^a   Sheng, Q ^d   Fletcher, J A ^c   Ou, W B ^a,c,d  

^a TSINGHUA UNIVERSITY   (China)

^b JIAXING UNIVERSITY   (China)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d ZHEJIANG SCI TECH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; DACTOLISIB; EVEROLIMUS; GEFITINIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; PROTEIN TYROSINE KINASE; RAF PROTEIN; SHORT HAIRPIN RNA;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE CHECKPOINT; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; MESOTHELIOMA; MESOTHELIOMA CELL LINE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BUTADIENES; CELL CYCLE; CELL LINE, TUMOR; CHROMONES; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; HUMANS; IMIDAZOLES; INDAZOLES; MAP KINASE SIGNALING SYSTEM; MESOTHELIOMA; MOLECULAR TARGETED THERAPY; MORPHOLINES; NEOPLASM PROTEINS; NITRILES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; QUINOLINES; RAF KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SIROLIMUS; SULFONAMIDES; TOR SERINE-THREONINE KINASES;

EID: 84900539635     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.220     Document Type: Article

References (47)

1. AltomareDA, YouH, XiaoGH, Ramos-NinoME, Skele KL,De RA, Jhanwar SC, Mossman BT, Kane AB, Testa JR (2005) Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically t o inhibit tumor cell growth. Oncogene 24: 6080-6089.
2. Brevet M, Shimizu S, Bott MJ, Shukla N, Zhou Q, Olshen AB, Rusch V, Ladanyi M (2011) Coactivation of receptor tyrosine kinases in maligna nt mesothelioma as a rationale for combination targeted therapy. J Thorac Oncol 6: 864-874.
3. Carbone M, Yang H (2012) Molecular pathways: Targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res 18: 598-604.
4. Carracedo A, Ma L, Teruya-Feldstein J, Ro jo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dep endent feedback loop in human cancer. J Clin Invest 118: 3065-3074.
5. Cedres S, Montero MA, Martinez P, Martinez A, Rodriguez-Freixinos V, Torrejon D, Gabaldon A, Salcedo M, Ramon YC, Felip E (2012) Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). Lung Cancer 77: 192-198.
6. Cheng X, Xia W, Yang JY, Hsu JL, Lang JY, C hou CK, Du Y, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC (2010) Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis. Cance r Res 70: 7684-7689.
7. Craighead JE (1987) Current pathogenetic concepts of diffuse malignant mesothelioma. Hum Pathol 18: 544-557.
8. Cole JrGW, Alleva AM, Zuo JT, Sehgal SS, YeowWS, SchrumpDS, Nguyen DM (2006) Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126. Anticancer Res 26: 809-821.
9. D emetri GD, Zenzie BW, Rheinwald JG, Griffin JD (1989) Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro. Blood 74: 940-946.
10. Fischer B, Frei C, Moura U, Stahel R, Felley-Bosco E (2012) Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy. Lung Cancer 78: 23-29.
11. Gordon GJ, Rockwell GN, Jensen RV, Rheinwald JG, Glickman JN, Aronson JP, Pottorf BJ, Nitz MD, Richards WG, Sugarbaker DJ, Bueno R (2005) Identification of novel candidate oncogenes and tumor su ppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol 166: 1827-1840.
12. Govindan R, Kratzke RA, Herndon JE, Niehans GA, Vollmer R, Watson D, Green MR, Kindler HL (2005) Gefitinib in patients with malignant mesothelioma: A phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 11: 2300-2304.
13. Harvey P, Clark IM, Jaurand MC, Warn RM, Edw ards DR (2000) Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases. Br J Cancer 83: 1147-1153.
14. Herzog A, Bian Y, Vander B roek R, Hall B, Coupar J, Cheng H, Sowers AL, Cook JD, Mitchell JB, Chen Z, Kulkarni AB, Van Waes C (2013) PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xe nograft and murine knockout models of head and neck cancer. Clin Cancer Res 19: 3808-3819.
15. Jacobson BA, De A, Kratzke MG, Patel MR, Jay-Dixon J, Whitson BA, Sadiq AA, Bitterman PB, Polunovsky VA, Kratzke RA (2009) Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma. Br J Cancer 101: 424-431.
16. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadees waran S, Zumba O, Nallasura V, Ahmed S, Filiberti R, Paganuzzi M, Puntoni R, Kratzke RA, Gordon GJ, Sugarbaker DJ, Bueno R, Janamanchi V, Bindokas VP, Kindler HL, Salgia R (2006) Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 66: 352-361.
17. Janne PA Taffaro ML Salgia R Johnson BE 2002 Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma Cancer Res 62 5242-5247.
18. Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, Fukui T, Kondo Y, Osada H, Usami N, Yokoi K, Ueda Y, Yatabe Y, Ito M, Horio Y, Hida T, Sekido Y (2009) Combined inhibition of MET and EGFR suppresses prol iferation of malignant mesothelioma cells. Carcinogenesis 30: 1097-1105.
19. Klominek J, Baskin B, Liu Z, Hauzenberger D (1998) Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of mal ignant mesothelioma cells through c-met receptor. Int J Cancer 76: 240-249.
20. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10: 594-601.
21. Mathy A, Baas P, Dalesio O, Van ZN (2005) Limited efficacy of imatinib mesylate in malignant mesothelioma: A phase II trial. Lung Cancer 50: 83-86.
22. Menges CW, Chen Y, Mossman BT, Chernoff J, Yeung AT, Testa JR (2010) A phosphotyrosine proteomic screen identifies multiple tyrosine kinase signaling pathways aberrantly activated in malignant mesothelioma. Genes Cancer 1: 493-505.
23. Menges CW, Sementino E, Tal archek J, Xu J, Chernoff J, Peterson JR, Testa JR (2012) Group I p21-activated kinases (PAKs) promote tumor cell proliferation and survival through the AKT1 and Raf-MAPK pathways. Mol Cancer Res 10: 1178-1188.
24. Miyoshi S, Hamada H, Hamaguchi N, Kato A, Katayama H, Irifune K, Ito R, Miyazaki T, Okura T, Higaki J (2012) Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitr o and in vivo. Int J Oncol 41: 449-456.
25. Mukohara T, Civiello G, Davis IJ, Taffaro ML, Christensen J, Fisher DE, Johnson BE, Janne PA (2005) Inhibition of the met receptor in mesothelioma . Clin Cancer Res 11: 8122-8130.
26. Okamoto J, Mikami I, Tominaga Y, Kuchenbecker KM, Lin YC, Bravo DT, Clement G, Yagui-Beltran A, Ray MR, Koizumi K, He B, Jablons DM (2008) Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma. J Thorac Oncol 3: 1089-1095.
27. Ou WB, Corson JM, Flynn DL, Lu WP, Wise SC, Bueno R, Sugarbaker DJ , Fletcher JA (2011a) AXL regulates mesothelioma proliferation and invasiveness. Oncogene 30: 1643-1652.
28. Ou WB, Hubert C, Corson JM, Bueno R, Flynn DL, Sugarbaker DJ, Fletcher JA (2011b) Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma. Neoplasia 13: 12-22.
29. Pache JC, Janssen YM, Walsh ES, Quinlan TR, Zanella CL, Low RB, Taatjes DJ, Mossman BT (1998) Increased epidermal growth factor-receptor protein in a human mesothelial cell line in response to long asbestos fibers. Am J Pathol 152: 333-340.
30. Patel MR, Jacob son BA, De A, Frizelle SP, Janne P, Thumma SC, Whitson BA, Farassati F, Kratzke RA (2007) Ras pathway activation in malignant mesothelioma. J Thorac Oncol 2: 789-795.
31. Perrone F, Jocolle G, Pennati M, Deraco M, Baratti D, Brich S, Orsenigo M, Tarantino E, De MC, Bertan C, Cabras A, Bertulli R, Pierotti MA, Zaffaroni N, Pilotti S (2010) Receptor tyrosine ki nase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. Eur J Cancer 46: 2837-2848.
32. Pinato DJ, Mauri FA, Lloyd T, Vaira V, Casadio C, Boldorini RL, Sharma R (2013) The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma. Br J Cancer 108: 621-628.
33. Pinton G, Manente AG, Angeli G, Mutt i L, Moro L (2012) Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma. PLoS One 7: E36856.
34. Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, Moskatel E, Baselga J, Guichard S, Rosen N (2011) mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov 1: 248-259.
35. Rubin B P, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA (2001) KIT activation is a ubiquitous feature of gastrointestinal strom al tumors. Cancer Res 61: 8118-8121.
36. Sahin AA, Coplu L, Selcuk ZT, Eryilmaz M, Emri S, Akhan O, Baris YI (1993) Malignant pleural mesothelioma caused by environmental exposure to asbestos or erionite in rural Turkey: CT fInDiNgS In 84 PaTiEnTs. AJR Am J ROeNtGeNoL 161: 533-537.
37. Selcuk ZT, Coplu L, Emri S, Kalyoncu AF, Sahin AA, Baris YI (1992) Malignant pleural mesothelioma due to e nvironmental mineral fiber exposure in Turkey. Analysis of 135 cases. Chest 102: 790-796.
38. Shukla A, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, Butnor KJ, Pass HI, Carbone M, Testa JR , Heintz NH, Mossman BT (2011) ERK2 is essential for the growth of human epithelioid malignant mesotheliomas. Int J Cancer 129: 1075-1086.
39. Singh S Ramamoorthy M Vaughan C Yeudall WA Deb S Palit DS 2013 Human oncoprotein MDM2 activates the Akt signaling pathway through an interaction with the repressor element-1 silencing transcription factor conferring a survival advantage to cancer cells Cell Death Differ 20 5 8-566.
40. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening.J. Nat l Cancer Inst 82: 1107-1112.
41. Suzuki Y, Murakami H, Kawaguchi K, Tanigushi T, Fujii M, Shinjo K, Kondo Y, Osada H, Shimokata K, Horio Y, Hasegawa Y, Hida T, Sekido Y (2009) Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Report 2: 181-188.
42. Tolnay E, Kuhnen C, Wiethege T, Konig JE, Voss B, Muller KM (1998) Hepatocyte growth factor/ scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. J Cancer Res Clin Oncol 124: 291-296.
43. Varghese S, Chen Z, Bartlett DL, Pingpank JF, Libutti SK, Steinberg SM, Wunderlich J, Alexander Jr. HR (2011) Activation of the phosphoinositide-3- kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma. Cancer 117: 361-371.
44. Wendel HG, De SE, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428: 332-337.
45. Xia G, Kumar SR, Masood R, Koss M, Templeman C, Quinn D, Zhu S, Reddy R, Krasnoperov V, Gill PS (2005) Up-regulation of EphB4 in mesothelioma and its biological significance. Clin Cancer Res 1 1: 4305-4315.
46. Zanella CL, Posada J, Tritton TR, Mossman BT (1996) Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the e pidermal growth factor receptor. Cancer Res 56: 5334-5338.
47. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC (2001) HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 3: 973-982.